Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer

ABSTRACT: H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer

PROVIDER: PRJNA835482 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19100653.fastq.gz	Fastqsanger.gz
	SRR19100654.fastq.gz	Fastqsanger.gz
	SRR19100655.fastq.gz	Fastqsanger.gz
	SRR19100656.fastq.gz	Fastqsanger.gz
	SRR19100657.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer

Project description:The study was performed to identify the role of H3K9 methylation in prostate cancer. This experiment was conducted to determine the genomic localization of H3K9me2 and H3K9me3 in naïve, short-term antiandrogen treated and antiandrogen resistant prostate cancer cells.

2022-05-05 | GSE202335 | GEO

H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.

Project description:Antiandrogen strategies remain the prostate cancer treatment backbone, but drug resistance develops. We show that androgen blockade in prostate cancer leads to derepression of retroelements (REs) followed by a double-stranded RNA (dsRNA)-stimulated interferon response that blocks tumor growth. A forward genetic approach identified H3K9 trimethylation (H3K9me3) as an essential epigenetic adaptation to antiandrogens, which enabled transcriptional silencing of REs that otherwise stimulate interferon signaling and glucocorticoid receptor expression. Elevated expression of terminal H3K9me3 writers was associated with poor patient hormonal therapy outcomes. Forced expression of H3K9me3 writers conferred resistance, whereas inhibiting H3K9-trimethylation writers and readers restored RE expression, blocking antiandrogen resistance. Our work reveals a drug resistance axis that integrates multiple cellular signaling elements and identifies potential pharmacologic vulnerabilities.

| S-EPMC9173765 | biostudies-literature

The effects of enzalutamide on androgen-dependent and androgen-independent prostate cancer cells.

Project description:To investigate the mechanisms of drug resistance and castration resistance in prostate cancer, we performed proteomic sequencing on androgen-dependent prostate cancer cells (LNCaP) and androgen-independent cells (AI) treated with enzalutamide.

2024-11-26 | PXD058261 |

Androgen receptor RIME in prostate cancer cells

Project description:Androgen receptor (AR) is a master transcription factor that drives prostate cancer (PCa) development and progression. Alterations in the expression or activity of AR coregulators significantly impact the disease's outcome. To identify all the essential components of the AR coregulator complex, we utilized a proteomic approach called rapid immunoprecipitation of endogenous proteins (RIME) to systematically identify all coregulator proteins of the AR interactome in PCa cells.

2022-07-12 | PXD031273 | Pride

Caloric restriction enhances the activity of anti-androgen therapy by inhibiting androgen receptor translation in prostate cancer

Project description:Epidemiological studies suggest that diet can impact the incidence, progression, and response to treatment of multiple cancers, including prostate cancer (PCa). In this study, we investigated the use of dietary interventions, specifically caloric or protein restriction, in combination with anti-androgen therapy as a treatment for PCa. We found that caloric restriction through alternate-day fasting (ADF) reduces androgen receptor (AR) expression and signaling. This reduction in AR enhances the antitumor activity of the AR antagonist enzalutamide in multiple mouse models of PCa. Mechanistic studies reveal that nutrient starvation via ADF predominantly decreases AR mRNA translation at the elongation stage due to amino acid limitation. Pharmacological agents that similarly impair translation elongation and promote ribosome collisions mimic the AR translation reduction observed with ADF. We propose that amino acid limitation through ADF impairs translation elongation in PCa, and AR mRNA translation is susceptible to this process, leading to a reduction in AR protein levels and enhancing AR-targeted therapy. This study suggests that fasting-induced caloric restriction may improve the efficacy of anti-androgen therapy in PCa.

2025-02-28 | GSE261842 | GEO

Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer

Project description:Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer

| PRJNA1214490 | ENA

Inflammation Impacts Androgen Receptor Signaling in Basal Prostate Stem Cells Through Interleukin 1 Receptor Antagonist

Project description:Inflammation Impacts Androgen Receptor Signaling in Basal Prostate Stem Cells Through Interleukin 1 Receptor Antagonist

| PRJNA1130057 | ENA

Inflammation Impacts Androgen Receptor Signaling in Basal Prostate Stem Cells Through Interleukin 1 Receptor Antagonist

Project description:Inflammation Impacts Androgen Receptor Signaling in Basal Prostate Stem Cells Through Interleukin 1 Receptor Antagonist

| PRJNA1122569 | ENA

ANDROGEN DRIVES MELANOMA INVASIVENESS AND METASTATIC SPREAD BY INDUCING TUMORIGENIC FUCOSYLATION: Fucoproteomics

Project description:Melanoma incidence and mortality rates are historically higher for men than women. Although emerging studies have highlighted tumorigenic roles for the male sex hormone androgen and its receptor (AR) in melanoma, cellular and molecular mechanisms underlying these sex-associated discrepancies are poorly defined. Here, we delineate a previously undisclosed mechanism by which androgen-activated AR transcriptionally upregulates fucosyltransferase 4 (FUT4) expression, which drives melanoma invasiveness by interfering with adherens junctions (AJs). Global phosphoproteomic and fucoproteomic profiling, coupled with in vitro and in vivo functional validation, further reveals that AR-induced FUT4 fucosylates L1 cell adhesion molecule (L1CAM), which is required for FUT4-increased metastatic capacity. Tumor microarray and gene expression analyses demonstrate that AR-FUT4-L1CAM-AJs signaling correlates with pathological staging in melanoma patients. By delineating key androgen-triggered signaling that enhances metastatic aggressiveness, our findings help to explain sex-associated clinical outcome disparities and highlight AR/FUT4 and its effectors as potential prognostic biomarkers and therapeutic targets in melanoma.

2024-01-15 | PXD047337 | Pride

ANDROGEN DRIVES MELANOMA INVASIVENESS AND METASTATIC SPREAD BY INDUCING TUMORIGENIC FUCOSYLATION: Phosphoproteomics

2024-01-15 | PXD047335 | Pride